The researchers systematically analyzed the risk of malformations following the use of proton pump inhibitors (PPIs) during the first trimester of pregnancy.
They published the results of their study in Digestive Diseases & Sciences.
PPIs are used to treat gastroesophageal reflux, a symptom common in pregnancy.
Medline, EMBASE, published abstracts, and reference lists were searched for articles reporting on PPI use in pregnancy.
| Relative risk of malformation when taking PPIs during pregnancy: 1.18.
| Digestive Diseases & Sciences |
Summary relative risks were calculated using the Mantel-Haenszel method.
The authors found 5 cohort studies that met the inclusion criteria for the meta-analysis.
With almost 600 exposed pregnancies, the overall relative risk of major malformations was 1.18.
Shekoufeh Nikfar, of the Hospital for Sick Children, Toronto, concluded on behalf of fellow authors, "PPIs do not present a major teratogenic risk when used in recommend doses.
"These data are reassuring for the countless patients who have used these agents in the early part of their pregnancies."